CJD-Implicated Blood Recall Exemption Under Consideration By FDA
Executive Summary
FDA is discussing a recall exemption for blood products from CJD-implicated batches if manufacturers have well-defined standard operating procedures, FDA Laboratory of Plasma Derivatives Senior Fellow Dorothy Scott, MD, told a Blood Safety & Screening conference in McLean, Va. Feb. 23.